Basel, March 31, 2014 - Novartis announced today that the Data Monitoring Committee (DMC) unanimously recommended early closure of the PARADIGM-HF study, indicating patients with chronic heart failure with reduced ejection fraction (HF-REF) who received LCZ696 lived longer without being hospitalized for heart failure than those who received standard care with ACE-inhibitor enalapril.
Basel, March 26, 2014 - Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.
北京，2014年3月26日 – 诺华宣布，欧盟已批准在H1抗组胺药疗效不佳的慢性自发性荨麻疹（CSU）成人和青少年患者（≥12岁）中联用Xolair®（奥马珠单抗）。批准剂量为300 mg，皮下注射给药，每4周1次。
Basel, 22 March 2014 - Novartis announced results from the pivotal phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, demonstrated consistent high efficacy when administered with a convenient pre-filled syringe (PFS) or autoinjector/pen (AI),.
Basel, 21 March 2014 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is known as chronic spontaneous urticaria (CSU) outside of the US.
Basel, 21 March, 2014 - Novartis announced today that the Joint Committee on Vaccination and Immunisation (JCVI) in the UK has recommended the inclusion of Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) in the National Immunisation Programme.
Basel, 21 March 2014 - Novartis announced today that a new phase IIIb head-to-head study of IL-17A inhibitor secukinumab (AIN457) versus Stelara® (ustekinumab) in moderate-to-severe plaque psoriasis has started patient enrollment.
Basel, March 19, 2014 - Results from the secondary endpoint of the Phase III BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) study of Afinitor® (everolimus) trial were presented today at the 9th European Breast Cancer Conference (EBCC-9) in Glasgow, Scotland.